<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><copyright>(C) Copyright 2004-2026 Pillole.org - Tutti i diritti riservati</copyright><title>Le Ultime Pillole</title><description>Pillole di medicina telematica Informazione professionale medica </description><atom:link href="http://www.pillole.org/public/aspnuke/newsxml.asp?xmlid=6408" rel="self" type="application/rss+xml" /><link>http://www.pillole.org/public/aspnuke/newsxml.asp?xmlid=6408</link><pubDate>Wed, 8 Apr 2026 01:58:35 +0100</pubDate><docs>http://www.pillole.org/public/aspnuke/news.asp?id=6408</docs><generator>Pillole.org</generator><category>News</category><managingEditor>info@pillole.org (Luca Puccetti)</managingEditor> <webMaster>info@pillole.org (Luca Puccetti)</webMaster><language>it-it</language><image><title>Le Ultime Pillole</title><url>http://www.pillole.org/klip/logopillolesmall.gif</url><link>http://www.pillole.org/public/aspnuke/newsxml.asp?xmlid=6408</link><width>16</width><height>16</height><description>Pillole di medicina telematica</description></image><item><pubDate><![CDATA[Sun, 27 Sep 2015 00:00:00 +0100]]></pubDate><title><![CDATA[Empagliflozin riduce eventi cardiovascolari nei diabetici ad alto rischio]]></title><description><![CDATA[Lo studio EMPA-REG OUTCOME suggerisce che l'empagliflozin (un inibitore del SGLT-2) riduce la mortalita` in diabetici tipo 2 ad alto rischio.
]]></description><link><![CDATA[http://www.pillole.org/public/aspnuke/news.asp?id=6408]]></link><guid><![CDATA[http://www.pillole.org/public/aspnuke/news.asp?id=6408]]></guid></item></channel></rss>